ArticleDermatology and therapy2025

Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis.

Emma Guttman-Yassky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.